The initial success of the copyright undeniably transformed the drug landscape, but betting in companies heavily reliant on unbranded versions presents a complex picture. While early earnings were significant, the cessation of patents and the appearance of discounted alternatives have eroded sales. Thus, a thorough assessment of present financial p